Five Oceans Advisors boosted its stake in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 6.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,049 shares of the company’s stock after purchasing an additional 819 shares during the period. Novo Nordisk A/S comprises about 1.1% of Five Oceans Advisors’ holdings, making the stock its 19th largest holding. Five Oceans Advisors’ holdings in Novo Nordisk A/S were worth $1,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of NVO. Jennison Associates LLC raised its stake in Novo Nordisk A/S by 731.0% during the 1st quarter. Jennison Associates LLC now owns 5,527,477 shares of the company’s stock worth $613,826,000 after buying an additional 4,862,299 shares during the period. BlackRock Inc. grew its position in shares of Novo Nordisk A/S by 45.4% in the first quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after purchasing an additional 1,571,747 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Novo Nordisk A/S during the 1st quarter worth about $60,695,000. Adage Capital Partners GP L.L.C. purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $58,800,000. Finally, Vantage Investment Partners LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $54,316,000. Institutional investors own 6.62% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. raised Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 7th. Guggenheim upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, May 31st. Exane BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a 750.00 price target for the company in a research report on Monday, June 27th. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $750.00 target price for the company in a report on Monday, June 27th. Finally, UBS Group lowered Novo Nordisk A/S from a “neutral” rating to a “sell” rating in a research note on Tuesday, June 28th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $682.43.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S Cuts Dividend
The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were given a $0.5836 dividend. The ex-dividend date of this dividend was Friday, August 12th. This represents a yield of 1.1%. Novo Nordisk A/S’s dividend payout ratio is currently 24.18%.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- The Institutions Hold On To Darden Restaurants International
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.